An Open-label, Single-arm Extension Study to Evaluate the Long-term Safety of Denosumab Administration in Postmenopausal Women With Low Bone Mineral Density.
Phase of Trial: Phase III
Latest Information Update: 03 Aug 2017
At a glance
- Drugs Denosumab (Primary)
- Indications Postmenopausal osteoporosis
- Focus Registrational; Therapeutic Use
- Sponsors Amgen
- 29 Jul 2013 Primary endpoints added as reported by ClinicalTrials.gov.
- 01 Aug 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 25 Aug 2009 Planned end date (Jan 2012) added as reported by ClinicalTrials.gov.